Research Analysts Offer Predictions for UBX FY2024 Earnings

Unity Biotechnology, Inc. (NASDAQ:UBX) – Equities researchers at Chardan Capital issued their FY2024 earnings estimates for Unity Biotechnology in a report issued on Sunday, January 12th. Chardan Capital analyst D. Gataulin forecasts that the company will earn ($1.41) per share for the year. Chardan Capital currently has a “Buy” rating and a $6.00 target price on the stock. The consensus estimate for Unity Biotechnology’s current full-year earnings is ($1.49) per share. Chardan Capital also issued estimates for Unity Biotechnology’s FY2025 earnings at ($0.74) EPS.

Unity Biotechnology Stock Down 1.2 %

Unity Biotechnology stock opened at $1.69 on Wednesday. The stock has a market cap of $28.48 million, a P/E ratio of -1.29 and a beta of 0.80. The company’s 50 day moving average price is $1.20 and its two-hundred day moving average price is $1.36. Unity Biotechnology has a 52 week low of $0.94 and a 52 week high of $2.02.

Unity Biotechnology (NASDAQ:UBX) last released its quarterly earnings data on Monday, November 4th. The company reported ($0.38) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.02.

Institutional Investors Weigh In On Unity Biotechnology

A hedge fund recently raised its stake in Unity Biotechnology stock. Geode Capital Management LLC increased its stake in Unity Biotechnology, Inc. (NASDAQ:UBX) by 9.5% in the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 163,242 shares of the company’s stock after acquiring an additional 14,199 shares during the period. Geode Capital Management LLC owned about 0.97% of Unity Biotechnology worth $240,000 as of its most recent SEC filing. 29.49% of the stock is owned by institutional investors and hedge funds.

About Unity Biotechnology

Unity Biotechnology, Inc, a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase 2 clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy.